Visudyne Powder For Solution For Injection 15Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Visudyne: Powder for solution for injection (15mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

VERTEPORFIN (VER te PORE fin) is used to treat macular degeneration. It is activated by light. This medication is given, then the eye(s) are treated with a laser light. This is called photodynamic therapy (PDT). This treatment results in a slowing of the disease and helps to maintain vision.

In-Depth Information
Select a Medication

Visudyne 15mg Powder for Injection

NDC: 001875600
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Macular Degeneration, Choroidal Neovascularization (CNV)

Sometimes used for but not FDA approved for the following conditions:
Central Serous Chorioretinopathy

Storage Information
Store between 68 to 77 degrees F
Visudyne 15mg Powder for Injection

Reported Side Effects for Visudyne 15mg Powder for Injection

Chest Pain Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Retinal Detachment Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Back Pain Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Conjunctivitis Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Double Vision Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Deafness Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Hypoesthesia Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Secretion Of Tears Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Muscle Weakness Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Visual Impairment Incidence:
1.0-5.0%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Anemia Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Joint Pain Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Irregular Heart Beat Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: EARLY
Inflamed Eyes Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Constipation Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Cough Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Itchy Eyes Incidence:
1.0-10.0%*
Severity: MILD
Onset: RAPID
Sore Throat Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Balance Problems Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Dry Eyes Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Cataracts Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Flu Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
High White Blood Cells Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Low White Blood Cell Counts Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Eye Pain Incidence:
10.0-30.0%*
Severity: MILD
Onset: EARLY
Eye Inflammation Incidence:
10.0-30.0%*
Severity: MODERATE
Onset: EARLY
Injection Site Reaction Incidence:
10.0-30.0%*
Severity: MILD
Onset: RAPID
Swelling Incidence:
10.0-30.0%*
Severity: MODERATE
Onset: DELAYED
Bleeding Within The Eye Incidence:
10.0-30.0%*
Severity: SEVERE
Onset: DELAYED
Blurred Vision Incidence:
10.0-30.0%*
Severity: MODERATE
Onset: EARLY
Skin Rash Incidence:
10.0-30.0%*
Severity: MILD
Onset: EARLY
Scotomata Incidence:
10.0-30.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Visudyne

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5